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C-terminal fragments of the 
amyloid precursor protein in 
cerebrospinal fluid as potential 
biomarkers for Alzheimer disease
María-Salud García-Ayllón1,2,3, Inmaculada Lopez-Font1,2, Claudia P. Boix1,2, Juan Fortea2,4,5, 
Raquel Sánchez-Valle6, Alberto Lleó2,4, José-Luis Molinuevo6, Henrik Zetterberg7,8,9, Kaj 
Blennow7,8 & Javier Sáez-Valero1,2
This study assesses whether C-terminal fragments (CTF) of the amyloid precursor protein (APP) are 
present in cerebrospinal fluid (CSF) and their potential as biomarkers for Alzheimer’s disease (AD). 
Immunoprecipitation and simultaneous assay by Western blotting using multiplex fluorescence imaging 
with specific antibodies against particular domains served to characterize CTFs of APP in human CSF. We 
demonstrate that APP-CTFs are detectable in human CSF, being the most abundant a 25-kDa fragment, 
probably resulting from proteolytic processing by η-secretase. The level of the 25-kDa APP-CTF was 
evaluated in three independent CSF sample sets of patients and controls. The CSF level of this 25-kDa 
CTF is higher in subjects with autosomal dominant AD linked to PSEN1 mutations, in demented Down 
syndrome individuals and in sporadic AD subjects compared to age-matched controls. Our data suggest 
that APP-CTF could be a potential diagnostic biomarker for AD.
Accumulation of the β-amyloid peptide (Aβ) in the brain is an early and specific phenomenon associated with the 
pathogenesis of Alzheimer’s disease (AD)1. Many reports support that the determination of Aβ42 in cerebrospinal 
fluid (CSF) is a core biomarker for AD2. While the amount of the pathological species of Aβ is increased in the 
AD brain, their levels in CSF are decreased, probably due to increased brain deposition. To enable monitoring 
early disturbance in amyloid precursor protein (APP) and Aβ mis-metabolism additional biomarkers are needed.
Other plausible biomarkers for AD are additional fragments resulting from the processing of the amyloid 
precursor protein (APP). APP is a large type I transmembrane spanning protein consisting of a large N-terminal 
extracellular domain, a hydrophobic transmembrane domain, and a short intracellular C-terminal domain. APP 
is usually cleaved by α-secretase (ADAM10; leading to non-amyloidogenic pathway), or by β-secretase (BACE1; 
leading to amyloidogenic pathway), which causes the secretion of large sAPPα and sAPPβ N-terminal fragments 
(NTFs). CSF levels of sAPPα and sAPPβ show no change in AD3. The membrane remaining C-terminal frag-
ments (CTFs) are always processed by γ-secretase generating shortest intracellular domain (AICD) peptides (for 
a review see Haass et al.4).
APP can also undergo alternative proteolytic processing pathways (for a review see Andrew et al.5). Thereby, 
concerted cleavage of β-secretase and α-secretase result in the secretion of sAPPβ and shorter Aβ peptides6. 
The presence in CSF of short NTF derivatives of APP, which generation does not involve α-secretase or BACE, 
has been also demonstrated7. More interestingly in the context of this report, a recently discovered alternative 
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physiological APP processing pathway driven by an asparagine endopeptidase (AEP) named δ-secretase8 or by 
a metalloproteinase named η-secretase9 will generate alternative proteolytic metabolites, including NTFs and 
CTFs, of different molecular mass.
In addition to the different species of Aβ, all the large extracellular APP-NTFs have been studied in human 
CSF9–11; but the presence of APP-CTFs in CSF has not been reported to date. In this study we investigated if 
APP-CTFs are detectable in CSF, characterized the major APP-CTF immunoreactive band, and determined 
whether the levels of this peptide fragment are altered in autosomal dominant AD (ADAD), Down syndrome 
subjects with Alzheimer’s type dementia (dDS), and sporadic AD subjects (sAD).
Results
APP-CTFs are present in human CSF. To determine the presence of APP-CTFs in human CSF, we first 
examined human CSF samples by Western blotting using three different anti-CTF antibodies (a schematic rep-
resentation of APP and epitopes for antibodies is represented in Fig. 1A). This three APP-CTF antibodies demon-
strated specificity in assess the accumulation of C-terminal fragments of APP in cells transfected with a construct 
that encodes the C-terminal 99 amino acids of APP (amino acids 597–695; blots not shown). Immunoblotting 
revealed a similar pattern of immunoreactive bands, with a predominant band of ~25 kDa (Fig. 1B). This band 
was also observed with the 2D8 and 2E9 antibodies, both against an extracellular domain close to the transmem-
brane domain, thus recognizing a η-secretase-generated CTF-APP (CTFη)9. 2D8 and 2E9 also detected other 
soluble fragments around ~15 kDa, termed Aη, generated after concerted cleavage by η-secretase and α/β-secre-
tases9. 2D8 antibody also detected Aβ monomers. Multiplex fluorescence imaging with the A8717 and 2E9 anti-
bodies indicated that the major 25 kDa band is compatible with the CTFη; similar co-labelling was revealed with 
antibodies C1/6.1 and 2D8 (Supplemental Fig. 1). To further examine the identity of CTF bands in human CSF, 
we performed immunoprecipitation/Western blot analysis (Fig. 1C). Since in SDS-PAGE the immunoglobulin 
light chain migrates at similar molecular mass that the APP-CTF 25-kDa band, we used dimethyl pimelimidate 
dihydrochloride to covalently link primary antibodies to protein A Sepharose, and eluted with 0.1 M glycine 
buffer at pH 2.5, in order to prevent the co-elution of the antibody along with the target protein12. CSF samples 
were immunoprecipitated using the A8717 antibody and blotted with the Y188 antibody, confirming the identity 
Figure 1. Soluble CTFs of APP are present in human CSF. (A) Schematic representation of full-length APP 
processing by secretases. The epitopes for the antibodies used in this study are indicated. (B) Western blotting of 
three human CSF samples from non-demented controls subjects, resolved with the indicated antibody (samples 
were the same between different blots). (C) CSF aliquots (Total, T) were immunoprecipitated with the indicated 
antibody, and precipitated proteins (bound fraction, IP) were immunoblotted with the indicated alternative 
antibody. CSF aliquots incubated with protein A-Sepharose in the absence of capture-antibody (IPø) or with 
an irrelevant IgG (IPIg; a rabbit IgG for A8717 IP and a rat IgG for 2D8 IP), were analyzed in parallel as negative 
controls.
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of the 25-kDa band as an APP-CTF. Immunoprecipitating with 2D8 antibody and blotting with A8717 antibody 
supported the identity of the 25-kDa band as a CTFη.
The 25-kDa APP-CTF is increased in AD CSF. To assess whether APP-CTF levels are altered in AD, we 
first analyzed CSF samples from autosomal dominant AD (ADAD), an early-onset form of genetically deter-
mined AD13. Clinical, demographic data and classic CSF biomarker levels are included in Table 1. Genetically 
determined AD offers unique opportunities to analyze diagnostic biomarkers particularly given that diagnosis is 
guaranteed. The 25-kDa band was detected with A8717 antibody in all CSF analyzed (Fig. 2A). The immunoreac-
tivity of the 25-kDa APP-CTF band in the CSF from ADAD subjects increased (95 ± 27%; p = 0.01) compared to 
those in age-matched NC composed by non-mutation carriers from the same families (Fig. 2A). Down syndrome 
subjects with Alzheimer’s type dementia (dDS) can be also considered a form of genetically determined AD13. 
Once more, an increase (68 ± 18%; p = 0.01) in the intensity of the 25-kDa APP-CTF band, resolved with A8717 
antibody, was determined in CSF samples from dDS patients, comparing these to age-matched NC (Fig. 2B). 
Finally, we also have assessed potential differences in the level of the 25-kDa APP-CTF band in sporadic AD 
subjects (sAD) compared to aged-matched controls (see Table 1). We found that the total immunoreactivity for 
this band, detected with the A8717 antibody, increased (35 ± 9%; p = 0.01) in sAD compared to age-matched NC 
subjects (Fig. 2C). CSF samples from sAD subjects also showed a similar increment for the 25-kDa band when 
they were analyzed with the 2D8 antibody (35 ± 9%; p = 0.01), correlating tightly with the estimation of the levels 
calculated with the A8717 antibody (R = 0.73; p < 0.001; Supplemental Fig. 2). There were no clear correlations 
between the level of the 25-kDa APP-CTF band and the levels of classical biomarkers, Aβ42, T-tau or P-tau, in 
either the control or sAD groups considered individually (Supplemental Fig. 3). Only when control and sAD 
subjects were pooled, a positive correlation emerged between immunoreactivity levels of the 25-kDa APP-CTF 
band with T-tau, and with P-tau levels (Supplemental Fig. 3).
Discussion
Here, we demonstrate that APP-CTFs are detectable in human CSF. Particularly, the most abundant solu-
ble APP-CTF, a 25-kDa fragment, is attributed to a CTF recently characterize as the result of proteolytic pro-
cessing by η-secretase (CTFη)9. Canonical APP proteolysis occurs via α- and β-secretases, resulting in CTFα 
and CTFβ with a molecular mass lower than 15 kDa; but novel APP-CTF that migrates ~25 kDa has also been 
described14. In addition to the described alternative pathways for APP7–9, other cleavages for APP could occur 
since non-canonical N-terminal APP fragments have been also identified in human CSF15. The precise charac-
terization of the APP-CTF 25-kDa fragment as a CTFη requires further confirmation. In this regard, the devel-
opment of pan-specific antibodies against the predicted N-terminus of CTFη could be valuable. Similarly to the 
reported by others15, attempts to immunoprecipitate the 25-kDa APP-CTF for sequencing were not fruitful. Since 
soluble full-length APP protein is also present in CSF, forming heteromers that co-immunoprecipitate with more 
abundant sAPPβ and sAPPα16, an enrichment process based in available APP C-terminal antibodies could result 
of lower efficient and specificity for APP-CTFs. Similar handicap will difficult development of a specific ELISA 
assay (discussed below).
As an intermediate of proteolytic process, the presence of any APP-CTF in CSF was unexpected. Anyhow, the 
presence in CSF of soluble forms of full-length membrane proteins containing the transmembrane and intra-
cellular domains is not an unusual finding16, 17. Early studies failed to detect short C-terminal fragments of APP 
in the medium of cultured cells18; but others suggested the release of largest APP-CTF fragments from cultured 
neural cells19. Moreover, a series of APP-CTFs was found to be secreted within exosomes in cultured cells20, as 
well AICD21. The mechanisms by which these membrane-bound proteins reached the CSF are unknown; but neu-
ronal death may be also a major contributing factor. Regarding the cellular source of the soluble 25-kDa APP-CTF 
found in CSF, the presence of hitherto undocumented APP fragments, including a 25-kDa CTF, has been docu-
mented in hippocampal neurons9, but also across other multiple cell types, including bovine brain microvascular 
endothelial cells15. Since the δ-secretase enzyme AEP is a widely distributed22, we could not discard a non-neural 
source for the 25-kDa APP-CTF found in CSF. The cellular origin of the 25-kDa APP-CTF could be also relevant 
in order to define their potential as an AD biomarker.
Different APP C-terminal antibodies confirmed the 25 kDa as the predominant band in human CSF. As stated, 
these APP proteolytic fragments are derived from a constitutive processing step driven by a η-secretase that is 







sAD 71 ± 2 [55–86] 15F/5M 412 ± 19** 665 ± 52** 84 ± 6**
NC 72 ± 2 [57–88] 6F/14M 739 ± 32 233 ± 14 36 ± 2
ADAD 43 ± 2 [31–49] 5F/2M 266 ± 49** 883 ± 204** 168 ± 69*
NC 39 ± 3 [25–47] 5F/2M 809 ± 94 245 ± 29 46 ± 4
dDS 53 ± 2 [43–57] 4F/3M 422 ± 17* 767 ± 170* 108 ± 19*
NC 48 ± 2 [47–53] 5F/2M 751 ± 84* 160 ± 26 33 ± 5
Table 1. Clinical, demographic data and classic CSF biomarker levels. The PSEN1 mutations included in this 
study from ADAD cases (autosomal dominant AD subjects) corresponded to 3 carriers of L286P, and one 
S169P, L173F, L235R and L282R. The data represent the means ± SEM, and for age the range of values is also 
indicated. All the pathological groups were compared with age-matched NC obtained from the same Hospital. 
Significantly different **p < 0.005; *p < 0.05 from the NC group.
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partially in dynamic equilibrium with α- and β-secretase-mediated proteolysis9, 23, 24. The current canonical views 
about APP-related cleavage events are likely a partial understanding of the overall process. How secretases com-
pete for the APP substrate and whether subcellular compartmentalization of APP and secretases is responsible 
of the dynamic equilibrium between secretases is under discussion25. Thus, one may speculate that the particular 
abundance of the 25-kDa CTFη in CSF is related with compartmentalization of secretases, resulting in prolonged 
time of residence of these CTFη in comparison with canonical CTFα and CTFβ. Anyhow, the other fragments 
derived of the further processing of CTFη by α- and β-secretases, the Aη-α and Aη-β fragments, have been also 
identified in human CSF with levels similar than those for Aβ9.
Our determination of the 25-kDa APP-CTF levels by Western blotting displayed overlapping values between 
sAD and controls, whereas superior discrimination was obtained for ADAD and dDS subjects, compared to their 
respective controls. Interestingly, APP CTFβ levels are also elevated in frontal cortex brain homogenates obtained 
from ADAD patients26. Further studies will indicate if distinct pattern of APP processing in ADAD and sAD 
affect the generation of different APP-CTFs. Given that this is the first report that address the levels of APP-CTF 
in CSF, in order to prevent influence of pre-analytical confounding factors, in our study each pathological group 
was compared with age-matched controls obtained from the same center, with same volume of CSF taken, stored 
in aliquot of same volume and for similar period of time; and avoiding freeze/thaw cycles. Further studies are 
required to determine whether limiting pre-analytical confounding factors (discussed in del Campo et al.27), have 
a significant impact on the measured levels of APP-CTF by Western blotting. The possibility that APP-CTF levels 
varies with age should also be considered and deserve a specific study with a larger number of samples.
In our statistical analysis high levels of the 25-kDa APP-CTF in CSF correlated with increased concentration 
of T-tau and P-tau, but failed to correlate with Aβ42 levels. Increased concentration of T-tau in CSF is believed to 
reflect neurodegeneration whereas P-tau is supposed to reflect tangle pathology. Otherwise, the overall decrease 
in Aβ42 concentration in the CSF patients is not illustrative of imbalances in the brain APP processing, since in 
parallel with the increase in the generation of Aβ42, there will be an increment in Aβ aggregation with subsequent 
deposition. Thus, the positive correlations of the 25-kDa APP-CTF with T-tau and P-tau suggest a correlation 
with AD pathological process, but it is not possible to interpret links with altered APP processing. Anyhow, 
the mentioned correlations resulted positive only when all samples were considered, and not in control or sAD 
groups considered separately. Thus, these correlations obtained by pooling controls and demented subject, could 
be artefactual, driven by the anchoring effect of the control values. Further analysis with a large number of sam-
ples is required.
Figure 2. Higher levels of the 25-kDa APP-CTF band in the CSF of AD subjects. (A) Representative blot of 
the 25-kDa APP-CTF in the CSF samples from 7 symptomatic ADAD and 7 age-matched NC, which were 
from the same families that ADAD subjects but that did not carry mutations (black symbol; see also Table 1). 
Densitometric quantification of the immunoreactivity from the 25-kDa band is also shown. (B) Representative 
blot and densitometric quantification in CSF from 7 DS subjects with dementia of the Alzheimer’s type (dDS) 
and 7 age-matched NC. (C) Representative blot and densitometric quantification of the immunoreactivity from 
the 25-KDa APP-CTF in CSF samples from 20 sAD and 20 age-matched NC subjects. Immunodetections for 
(A, B, C) were performed with the A8717 antibody. p values are displayed.
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In term to define the true potential of the 25-kDa APP-CTF as a CSF biomarker, it will be valuable to rep-
licate our present finding using techniques such as ELISA. However, this desirable outcome will be challeng-
ing. As advanced above, we have described that the soluble full-length APP, containing the C-terminal domain, 
also exists in CSF as heteromeric complexes compromising other sAPP species16, and transmembrane domain, 
as well intracellular C-terminal domain could participate in APP dimerization (discussed in Isbertet et al.28). 
Indeed, intracellular CTF aggregates have been described with the participation of Aβ29 and heparan sulfate 
degradation products30, suggesting that other APP fragments and other proteolytic sub-products could inter-
act with APP-CTFs. Thus, future studies should develop custom pan-specific antibodies targeting the predicted 
N-terminal sequence of the APP-CTFs present in CSF, maybe including pretreatment methods designed to dis-
aggregate peptides31, for preventing co-precipitation of other APP fragments. Anyhow, even the disadvantages of 
Western blotting for quantitative analysis, we considered demonstrated that accumulation of APP-CTFs in CSF 
constitute a potential new biomarker of AD.
In resume, to our knowledge, the possibility that APP-CTFs can be assessed in the CSF has thus far not been 
considered. In this study, we demonstrate noticeable amounts of APP-CTFs in human CSF. Particularly, a 25-kDa 
APP-CTF appears increased in genetically determined AD, as well as in sAD. Our present findings provide suf-
ficient evidence to justify further studies on the determination of APP-CTFs as a potential new diagnostic bio-
marker of AD.
Material and Methods
Patients. Lumbar CSF samples were obtained from autosomal dominant AD (ADAD) subjects that were 
all carriers of PSEN1 mutations and who were part of the Genetic Counseling Program for familiar dementia 
(PICOGEN) at the Hospital Clínic (Barcelona, Spain). This group included 7 subjects carrying PSEN1 mutations, 
and 7 age-matched non-mutation carriers from the same families (non-disease controls: NC). We also included 
lumbar CSF samples from 7 Down syndrome subjects with Alzheimer’s type dementia (dDS), along with 7 age-
matched NC obtained from the Hospital Sant Pau (Barcelona, Spain). In addition, 20 subjects with sporadic 
AD (sAD) defined as patients with cognitive symptoms and a CSF biomarker profile indicating AD (high total 
tau and phosphorylated tau together with low Aβ42 levels; see Table 1) and 20 age-matched controls defined as 
patients with non-specific symptoms without neurochemical evidence of AD were also obtained from the Clinical 
Neurochemistry Laboratory (Mölndal, Sweden). All AD patients fulfilled the 2011 NIA-AA criteria for dementia32. 
This study was approved by the ethic committee at the Miguel Hernandez University and it was carried out in 
accordance with the Declaration of Helsinki. All patients (or their nearest relatives) and controls gave informed 
consent to participate in the study.
Western blotting and immunoprecipitation. Samples of CSF (30 µL) were denatured at 98 °C for 5 min 
and were resolved by electrophoresis on 16.5% Tris-Tricine gels. Following electrophoresis, proteins were blot-
ted onto nitrocellulose membranes (Schleicher & Schuell Bioscience, GmbH, Dassel, Germany). CTFs of APP 
were detected using the following anti-APP C-terminal antibodies: C1/6.1 (mouse monoclonal; Covance Inc, 
Princeton, USA), A8717 (rabbit polyclonal; Sigma Aldrich Co, St. Louis, MO), and Y188 (rabbit monoclonal; 
Abcam, Cambridge, UK), as well as with the rat antibodies 2D8 and 2E99. Multiplex fluorescence with two of the 
independent antibodies served to assess the specificity of the bands. Blots were then probed with the appropriate 
conjugated secondary antibodies (IRDye 680RD goat anti-rabbit; IRDye 680RD goat anti-mouse; and IRDye 
800CW goat anti-rat from LI-COR Biosciences Lincoln) and imaged on an Odyssey Clx Infrared Imaging System 
(LI-COR Bioscences). Band intensities were analyzed using LI-COR software (Image Studio Lite). A control CSF 
sample was used to normalize the immunoreactive signal between blots.
For immunoprecipitation, samples were precleared for 2 h at 4 °C by incubation with protein A-Sepharose 
(Sigma Aldrich Co). Immunoprecipitations were performed overnight at 4 °C by incubating 150 µL of CSF with 
the indicated anti-APP antibody. The antibody was previously coupled to protein A-Sepharose using dimethyl 
pimelimidate dihydrochloride (Sigma Aldrich Co). A rabbit IgG and a rat IgG (Vector) were used as control 
antibodies for immunoprecipitations. Precipitated proteins were washed with PBS and eluted with 0.1 M glycine 
buffer at pH 2.5. After pH neutralization, supernatants were denatured in Laemmli sample buffer at 98 °C for 
5 min and subjected to SDS-PAGE. The membranes were then probed with an alternative anti-APP antibody.
Measurement of T-tau, P-tau and Aβ42 by ELISA. Total tau (T-tau), phosphorylated tau (P-tau) and 
Aβ1–42 (Aβ42) concentrations in CSF were measured using INNOTEST ELISA methods (Fujirebio Europe, 
Gent, Belgium).
Statistical analysis. All data were analyzed using SigmaStat (Version 3.5; Systac Software Inc.) by Student’s 
t test (two-tailed) for determination of exact p values. Correlation was assessed by linear regression. Results are 
presented as means ± SEM.
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